New Drugs of 2013, Part 2

Pharmacy TimesFebruary 2014 Autoimmune Disorders
Volume 80
Issue 2

Pharmacists can learn about new drugs approved by the FDA in 2013, including clinical indications, mechanisms of action, interactions, adverse reactions, and dosing guidelines.

New Drugs of 2013, Part 2

Michael A. Mancano, PharmD

Clinical Professor of Pharmacy Practice

Chair, Department of Pharmacy Practice

Temple University

School of Pharmacy

Clinical Consultant

Pennsylvania Hospital, Department of Pharmacy

Philadelphia, Pennsylvania


The following contributors have no relevant financial relationships with commercial interests to disclose.


Michael A. Mancano, PharmD

Pharmacy Times Office of Continuing Professional Education

Planning Staff—David Heckard; Maryjo Dixon, RPh; and Steve Lin, PharmD, RPh

Pharmacy Times

Editorial Staff—Kirk McKay

Educational Objectives

After completing this continuing education program, participants will be able to:

  • Discuss the clinical indications of the new drugs approved by the FDA in 2013.
  • Explain the various mechanisms of action of the drugs discussed within this program.
  • Recognize the clinically relevant drug interactions for the drugs reviewed in this program.
  • Identify the most common adverse reactions for the new drug approvals in 2013.
  • Explain the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.

Target audience: Pharmacists

Type of activity: Knowledge

Release date: February 12, 2014

Expiration date: February 12, 2016

Estimated time to complete activity: 2 hours

Fee: Free

Click here to view this activity.

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-14-003-H04-P. The activity is available for CE credit through February 12, 2016.

Recent Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs